INTRODUCTION
By the end of the 19 th century, the fruits of the new science of microbiology began to be realized and one discovery followed another with rapid succession. This year, 1998, celebrates the 100th anniversary of one of these important discoveries by the Japanese microbiologist Kiyoshi Shiga, who identified the etiologic agent of epidemic dysentery in Japan in 1898 (1, 2) . Shiga called this organism Bacillus dysenteriae, however its genus name was subsequently changed to Shigella to honor its discoverer and S. dysenteriae type 1 is still often referred to as Shiga's bacillus.
Dr. Shiga, just 26 years of age at the time of his discovery, was the student of Shibasaburo Kitasato, another pioneering Japanese microbiologist and founding director of The Kitasato Institute where we gather for this International Symposium Celebrating the Centennary of the Discovery of Shiga's bacillus. Among his many scientific achievements Dr. Kitasato showed that tetanus and diphtheria toxoids induce antibodies that actively and passively protect animals from their lethal effects (3) . These findings set the stage for the development of tetanus and diphtheria toxoid vaccines, which continue to be used to the present day and have contributed to the survival of countless millions of humans over the past century. Dr. Kitasato, trained in the laboratory of Robert Koch and Dr. Shiga, who later studied with Paul Ehrlich in Germany, believed that microbial pathogenesis could often be ascribed to soluble toxins and that anti-toxins and toxoid vaccines were the way to protect the host. It is interesting that 100 years after the discovery of Shiga's bacillus, and his own attempts to develop a toxoid vaccine and passive immunotherapy, (15) . With this information, treatment was changed from the toxic and sometimes lethal emetine regimen for amebiasis to antibiotics active against Shiga's bacillus, and the mortality rates plummeted from 20-25%, figures similar to the epidemics in Japan of the 1890's, to under 1 %.
In the summer of 1969 I was a post-doctoral infectious diseases fellow In order to prove the relevance of Gb3 binding to cytotoxicity , several groups including our own demonstrated that this activity of Shiga toxin was proportional to the amount of Gb3 in the cells employed in the assay (Table 3 ) (34) . By limiting dilution methods, we cloned hypersensitive as well as highly resistant HeLa cells from a standard ATCC HeLa cell line , and again sensitivity to toxin was proportion to the amount of Gb3 compared to the parent cells (35) . We also produced Gb3 deficient toxinresistant HeLa and Vero cells by incubating the cells with an inhibitor of neutral glycolipid synthesis, PDMP. We could restore the latter cells to the sensitive phenotype by means of liposomal fusion methods to insert (42)) cloned and sequenced the gene for the SLT-I/ VT-1 toxin from E. coli. The predicted sequence of the toxin B subunit was identical to the amino acid sequence we had obtained by standard protein sequencing methods for the B subunit of Shiga toxin from S. dysenteriae type 1 (43) . We also found a region of the A subunit with homology to the A subunit of the plant toxin ricin (41) , although the significance of this was uncertain at the time. In 1987, a group of Japanese workers including Yoshifumi Takeda, described the mechanism of action of ricin as an RNA N-glycosidase enzyme that removed the ribose from one specific adenine residue in 28 S ribosomal RNA, rendering it inactive in protein synthesis (44) . It was not long before the same group examined the mechanism of action of Shiga toxin, and demonstrated that it shared the identical enzymatic activity, including the identical rRNA target; in other words, Shiga toxin was procaryotic ricin. A decade ago, then, Shiga toxin from S. dysenteriae type 1 and some of the related toxins from E. coli had been purified, we knew the cell surface receptors and the mechanism of action of these toxins, we had genetic probes for the toxin genes, and it was strongly suspected that these toxins played a role in the pathogenesis of HUS associated with toxin-producing bacteria. which mediates iron regulation via the fur gene system. Third, the gene for the A subunit is upstream of the B subunit, separated by just 8 nucleotides. Fourth, the A subunit has two cysteines near the C terminus that form an interchain disulfide bond, within which is a tryptic proteolytic site. Toxin activity is increased dramatically by proteolytic nicking, and this appears to take place primarily within an intracellular compartment, and there is good evidence that this event is mediated by the intravesicular protease, furin (47) . Removal of the interchain loop by site-directed mutagenesis of one cysteine results in an initial enhancement of toxin activity, perhaps by another proteolytic event, but much less total activity at later times of incubation, apparently due to enhanced degradation of the toxin when the disulfide loop is not present (48) . Purification of Stx toxins and subunits in large scale quantity have permitted their crystallization and 3-dimensional constructions of the relationship of the A and B pentamer subunits (51, 52) . The crystal structure reveals the A1 subunit positioned above the B pentamer, with the linear A2 chain extending through the central hole of the B pentamer.
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The active site, by analogy to the crystal structure of ricin and the identification of key active site residues by site-directed mutagenesis, is a groove into which the substrate fits. The sites of interaction between the B pentamer and the terminal Gala l 4-Gal disaccharide of Gb3 have also been identified and the receptor site and its adjacent key residues are clearly identified (53) . Unfortunately, Stx 2 has not yet been successfully crystallized, and while it is assumed that it looks generally similar to Stx and Stx 1, the reasons for the major differences in its biological behavior remain unknown. established to evaluate the role of specific microorganisms as the etiologic agents of a disease; in like manner a set of postulates to evaluate the role of toxins in disease pathogenesis have been proposed (Table 5 ) (61) . As applied to the family of Shiga toxins we can affirm first that HUS associated with a diarrheal prodrome is due to Stx-producing organisms (postulate 1), although there are other causes of HUS. Second, we have been able to isolate and purify these toxins. Third, these toxins produce manifestations in experimental animals that resemble the human disease, including thrombotic microangiopathy, even if there is no model that fully reproduces the hallmarks of HUS in humans. Fourth, specific antibody blocks these toxin mediated manifestations in experimental models. These findings suggest the potential utility of developing toxin based immunological control measures for the Shiga toxin producing bacterial infection.
The Immediate Future, 1998 Future, -2003 The future is in many ways beginning with this historic meeting at the Kitasato Institute. In the course of this meeting, the clinical, epidemiological and biological features of shigellosis and STEC infections will be thoroughly reviewed, highlighting the prospects for developing new control measures. With respect to the Shiga toxins there are already clinical trials underway to fully examine the potential of adsorption of toxin in the intestinal lumen using a nonabsorbable receptor analogue (Synsorb-pk) (62) . This strategy aims at blocking toxin uptake to the systemic circulation by irreversibly binding toxin to a silica particle that will be excreted in the stool, however the toxin pool present in the bowel lumen may be of limited importance in pathogenesis, as the small amount of toxin needed for systemic manifestations may be absorbed directly at the site of the intimate attachment of the organisms to the mucosa.
The results of the current trials for prevention and treatment of HUS will become available in the next several years.
A second possibility for the next few years is the application of screening methods and possibly vaccines for the animal reservoirs in developed countries designed to reduce the contamination by STEC in the food supply. This will be difficult to implement, even in these wealthy countries, and will have little impact in the developing countries where STEC infections occur (63) but still appear to be uncommon (64) . Even if such measures are successfully implemented, they will not alter the problem associated with endemic and epidemic multi-drug resistant Shiga bacillus dysentery in the third world, because animals are not involved in the transmission of this highly human host-adapted organism (65 
